The ABCs of ovarian cancer immunology: IgA, B cells, and CTLs

Article Tools

• Email

  Thank you for your interest in spreading the word about Science Immunology.

  NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

  Your Email

  Your Name

  Send To

  Enter multiple addresses on separate lines or separate them with commas.

  You are going to email the following The ABCs of ovarian cancer immunology: IgA, B cells, and CTLs

  Message Subject (Your Name) has forwarded a page to you from Science Immunology

  Message Body (Your Name) thought you would like to see this page from the Science Immunology web site.

  Your Personal Message

  CAPTCHA

  This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

  Send Message
• Alerts

  Please log in to add an alert for this article.

  Log In with your AAAS ID

  Sign In to Email Alerts with your Email Address

  Email

  Log in
• Citation tools

  The ABCs of ovarian cancer immunology: IgA, B cells, and CTLs

  By Andrew Lichtman

  Science Immunology05 Mar 2021

  Intratumoral B cells in ovarian cancers produce IgA, which binds tumor antigens and inhibit tumor growth through myeloid cell–dependent mechanisms or by neutralization of secreted factors, and by antigen-nonspecific binding to poly-Ig receptor on cancer cells leading to transcytosis, which sensitizes the cells for CTL killing.

  Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
• Share

  The ABCs of ovarian cancer immunology: IgA, B cells, and CTLs

  By Andrew Lichtman

  Science Immunology05 Mar 2021

  Intratumoral B cells in ovarian cancers produce IgA, which binds tumor antigens and inhibit tumor growth through myeloid cell–dependent mechanisms or by neutralization of secreted factors, and by antigen-nonspecific binding to poly-Ig receptor on cancer cells leading to transcytosis, which sensitizes the cells for CTL killing.

  Share This Article: Copy